Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01460862 |
Recruitment Status : Unknown
Verified November 2017 by Novartis ( Novartis Pharmaceuticals ).
Recruitment status was: Active, not recruiting
First Posted : October 27, 2011
Last Update Posted : November 17, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Asthma |
Study Type : | Observational |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Analyze the Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations Among Patients With Uncontrolled Asthma Receiving High Dose Inhaled Corticosteroids |
Study Start Date : | May 2011 |

Group/Cohort |
---|
Omalizumab Cohort |
- Frequency of emergency-department visits and hospitalizations [ Time Frame: 12 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 12 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- ≥12 years of age with a documented Cystic fibrosis (CF) diagnosis,
- on Long acting Beta antagonist- Inhaled Corticosteroid (LABA-ICS) at baseline,
- uncontrolled asthma at baseline.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460862
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT01460862 |
Other Study ID Numbers: |
HEORUS0091 |
First Posted: | October 27, 2011 Key Record Dates |
Last Update Posted: | November 17, 2017 |
Last Verified: | November 2017 |
Asthma Omalizumab |
Asthma Emergencies Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Disease Attributes Pathologic Processes |